


Journal Pre-proof

Facilitating Activity and Self-management for people with Arthritic knee, hip or lower back pain (FASA): a cluster randomised controlled trial

Nicola Walsh, Louise Jones, Sonia Phillips, Rachel Thomas, Lang'o Odondi, Shea Palmer, Fiona Cramp, Jon Pollock, Mike Hurley



PII: S2468-7812(20)30576-2

DOI: <https://doi.org/10.1016/j.msksp.2020.102271>

Reference: MSKSP 102271

To appear in: *Musculoskeletal Science and Practice*

Received Date: 30 March 2020

Revised Date: 21 August 2020

Accepted Date: 5 October 2020

Please cite this article as: Walsh, N., Jones, L., Phillips, S., Thomas, R., Odondi, L.'o, Palmer, S., Cramp, F., Pollock, J., Hurley, M., Facilitating Activity and Self-management for people with Arthritic knee, hip or lower back pain (FASA): a cluster randomised controlled trial, *Musculoskeletal Science and Practice*, <https://doi.org/10.1016/j.msksp.2020.102271>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Crown Copyright © 2020 Published by Elsevier Ltd. All rights reserved.

TITLE PAGE

Facilitating Activity and Self-management for people with Arthritic knee, hip or lower back pain (FASA): a cluster randomised controlled trial.

Nicola Walsh PhD¹, Louise Jones MCSP¹, Sonia Phillips MCSP¹, Rachel Thomas MCSP¹, Lang'o Odondi PhD², Shea Palmer PhD¹, Fiona Cramp PhD¹, Jon Pollock PhD¹, Mike Hurley PhD³

¹Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK

²Division of Cardiovascular Medicine, University of Nottingham, UK

³School of Rehabilitation Sciences, University of London, UK

Address for Correspondence:

Professor Nicola Walsh

Faculty of Health and Applied Sciences

Glenside Campus

Blackberry Hill

Bristol, BS16 1DD

0117 328 8801

Nicola.walsh@uwe.ac.uk

Conflicts of Interest: None

Ethical Approval: 11/SW/0053

Funding: Chartered Society of Physiotherapy Charitable Trust

Clinical Trial Registry: ISRCTN registration 66190737

Background: Chronic musculoskeletal pain including osteoarthritis (OA) can significantly limit the functional independence of individuals. The spine and hip and knee are predominantly affected; management guidelines for each recommend exercise and education to support self-management.

Objectives: This study investigated the effectiveness of a generic exercise and self-management intervention for people over-50 with hip/knee OA and/or lower back pain compared to continued GP management.

Design: Single blind, cluster randomised controlled trial

Method: Participants who had previously consulted with hip/knee OA and/or chronic lower back pain were recruited from 45 GP practices in SW England. Practices were randomly allocated to receive continued GP care (control) or continued GP care and a 6-week group exercise and self-management intervention facilitated by a physiotherapist and located in a community-based physiotherapy department. The primary outcome measure was the Dysfunction Index of the Short Musculoskeletal Functional Assessment (DI-SMFA) measured at six month post-rehabilitation.

Results: 349 participants were recruited and allocated to the intervention (n=170) or control (n=179) arms; the attrition rate was 13% at the 6 month primary end-point. One minor adverse event in the intervention group that required no medical input was reported. Intervention arm participants reported better function at 6 months compared with continued GP management alone (-3.01 difference in DI-SMFA [95%CI -5.25, -0.76], p=0.01).

Conclusions: A generic exercise and self-management intervention resulted in statistically significant changes in function after six-months compared with GP management alone, but clinical significance of these findings is less clear. This may be an effective way of managing group interventions.

Journal Pre-proof

1 Facilitating Activity and Self-management for people with Arthritic knee, hip or lower back
2 pain (FASA): a cluster randomised controlled trial.

4 INTRODUCTION

5 As the population increases and people live longer, diseases associated with older age pose
6 a considerable public health issue ^[1]. Demands on already compromised health services are
7 likely to grow as individuals seek medical assistance to retain independence and quality of
8 life. Chronic musculoskeletal pain including osteoarthritis (OA) can significantly limit the
9 functional independence of individuals, and given that 25% of the population experience
10 these problems ^[2], the socioeconomic impact is immense and the personal impact
11 significant – musculoskeletal disorders are the single largest cause of years lived with
12 disability in the UK ^[3]. Pressure on the older individual to remain healthy will intensify in
13 association with the expectations to remain economically active and continue working into
14 the seventh decade.

15
16 Within primary care approximately one third of general practitioner (GP) consultations are
17 related to musculoskeletal disorders ^[4] the most prevalent of which are OA and chronic low
18 back pain ^[5]. These conditions are not life-threatening per se, but the effects of pain-
19 induced immobility and reduced function can contribute to the development and
20 progression of other serious comorbidities common in the older population (e.g. diabetes
21 and hypertension) ^[5]. Furthermore associated anxiety and depression are recognisably
22 higher in this group ^[6]. As such, from a public health perspective, reducing the impact of
23 these conditions is an important component of maintaining a healthy older population.

25 Although disabling chronic musculoskeletal pain and OA can present in any joint, the hip,
26 knee and lumbar spine are predominantly affected ^[7]. Previous research has demonstrated
27 the effectiveness of exercise and self-management ^[8], but most trials tailor interventions for
28 specific joints (e.g. hip or knee or back). In order to deliver evidence-based treatments
29 clinicians have either to manage patients on an individual basis or refer to joint-specific
30 group interventions. Neither option is ideal – the former incurs significant time and financial
31 cost, whilst the latter often requires patients to wait for appropriate numbers of people to
32 be referred to allow groups to run. Furthermore, epidemiological data demonstrate that
33 many older people with degenerative joint problems experience pain and functional
34 difficulty in other joints, seeking further healthcare input as these present ^[9].

35

36 Managing multiple joint presentations simultaneously may reduce the need for repeat visits
37 to healthcare professionals as advice is frequently similar for differing site presentations. In
38 addition, widening therapy to cover patients with multiple joint involvement would attract
39 more patients, enable classes to run more frequently (thus reducing waiting times) and
40 potentially have a prophylactic effect, as people would be more proactive in exercising the
41 whole musculoskeletal system.

42

43 NICE guidelines recommend exercise and education to promote self-management of the
44 condition ^[10]. Long-term engagement with exercise, like many lifestyle change
45 interventions, is generally limited, particularly in the presence of chronic musculoskeletal
46 pain. Many patients stop exercising once formal interventions cease because of loss of
47 interest, lack of time and/or facilities, and minimal benefits to pain or function ^[11].
48 Symptoms often return and re-referral for further intervention is common at considerable
49 cost to health services ^[9]. Previous work has demonstrated that for chronic knee pain/OA, a

50 six-week exercise and self-management intervention (ESCAPE-knee pain) facilitated by a
51 physiotherapist resulted in clinically and statistically significant improvements in function,
52 pain and self-efficacy six months post-intervention ^[12], which were still apparent 2½ years
53 later ^[13].

54 The current trial was undertaken to determine whether a modified version of the ESCAPE
55 programme, FASA – Facilitating Activity and Self-management in Arthritic Pain, based on
56 social cognitive theory, ^[14], was beneficial to people with lower limb OA, chronic low back
57 pain, or a combination of these presentations. The primary hypothesis was that
58 participation in the FASA intervention would improve function more effectively than
59 continued GP management alone.

60

61 **METHODS**

62 This trial was conducted and analysed according to a pre-specified protocol ^[15] (ISRCTN
63 registration 66190737). Ethical approval was received from South West 4 Research Ethics
64 Committee: Reference number 11/SW/0053. Recruitment, intervention and follow-up was
65 completed in 2016, analysis was completed in 2018.

66

67 **Design:** A pragmatic, assessor blinded, cluster randomised controlled trial (CRCT) compared
68 usual GP-led primary care management to a physiotherapist-facilitated exercise and self-
69 management intervention.

70

71 **Study sample and recruitment**

72 Broad inclusion criteria were adopted to reflect typical populations in primary care, and
73 participants were recruited from urban and rural GP practices in South West England.
74 Individuals were invited to participate if they were aged 50 years and over; and had a clinical

75 or radiographic diagnosis of hip and/or knee OA, and/or chronic lower back pain of at least
76 six months duration. Participants were excluded if they had received physiotherapy in the
77 preceding 6 months; had lower limb arthroplasty; had unstable medical or psychiatric
78 disorders; or their level of spoken English would prohibit group participation.

79 GP practices were recruited via the Clinical Research Network and were asked to perform a
80 database search and send an invitation letter to all potential participants. Subsequently,
81 practices were 4-block randomised to either the intervention arm or GP-led management
82 arm, using random sequence generation by a researcher located remotely who was not
83 involved in recruitment, assessment, data collection or analysis. Potential participants were
84 asked to return a reply slip or to telephone the Trial Co-ordinator who responded to
85 participant queries, screened potential participants, received written consent and arranged
86 assessment appointments, but was not involved in outcome assessment and remained blind
87 to individual outcome data. Patient groups were formed from the recruiting practices and
88 individuals attended at a site local to them.

89

90 The Trial Assessor, a physiotherapist blind to participant allocation, conducted the baseline
91 assessment at a local community-based out-patient physiotherapy department. The
92 assessment included administration of all outcome measures, collecting anthropometric
93 data and a physical assessment to eliminate any serious pathology that would exclude
94 individuals from participating.

95

96 **Sample size calculation:** Taking $p < 0.05$ as significant, the study sample size of $n = 352$ was
97 calculated to have 80% power to detect a 5.7 point absolute difference in the primary
98 outcome measure, the Dysfunction Index of the Short Musculoskeletal Functional
99 Assessment (DI-SMFA) ^[16] score at 6 months post intervention, between the group

100 intervention and standard care arms. Calculations assumed a mean score of 58 (SD=16)
101 would be observed in standard care, which is taken from Ponzer et al^[17] in a sample of 30
102 patients with chronic OA in the hip/knee.
103 As interventions were randomised at the GP practice level, sample size calculations
104 accounted for this design, assuming an average of 8 patients would be recruited per GP
105 practice (based on response of the original ESCAPE trial^[11] with cluster size standard
106 deviation (SD) of 5.11 (taken from the findings of Hurley et al^[11]). Variable cluster sizes were
107 accommodated using the formula of Eldridge et al^[17] anticipating an attrition rate of 20% at
108 the individual level by the primary end point, assumed to be independent of response and
109 cluster size. We used the same intra-cluster correlation co-efficient (ICC) =0.036 as was
110 reported by Hurley et al^[11] and assumed an overall response SD = 15.0 (in both arms).

111

112 **Intervention arm**

113 The FASA intervention was derived from the ESCAPE-knee programme^[12], with amendments
114 made to account for the involvement of multiple joints. It consisted of an exercise and self-
115 management intervention lasting 6-weeks (twice weekly), and was delivered by a
116 physiotherapist (blinded to assessment data) to closed groups of approximately eight
117 participants. In brief, each session lasted for 60-minutes and included approximately 20-25
118 minutes of physiotherapist-facilitated group discussion and problem-solving session (with a
119 supporting handbook) regarding issues of self-management. Topics included activity-rest
120 cycling, use of ice and heat for pain relief, goal-setting and action plans, exercise
121 recommendations, healthy eating and managing changes in pain. After each discussion,
122 participants undertook approximately 30-35 minutes of exercise, based on stations of
123 strengthening, aerobic and co-ordination activities. Further to the exercises, in collaboration
124 with the physiotherapist, each individual completed an action plan regarding

125 exercise/activities they aimed to achieve over the following week. This was reviewed after
126 each week, to determine adherence to the plan, problem-solving if the goal had proved
127 unachievable, or progressed if it was achieved. Each participant was provided with a
128 supplementary patient booklet that contained educational materials and self-completed
129 tasks to monitor their progress. *Patients in this arm were also permitted to continue on GP*
130 *management and all other treatments as prescribed except physiotherapy. Further details of*
131 *the specific behavioural change techniques employed in this intervention can be found*
132 *elsewhere*^[19].

133

134 *All groups were located within typical community-located physiotherapy out-patient*
135 *departments, no additional equipment was required, and all were integrated into standard*
136 *working hours. Groups were sequentially populated from recruited GP sites, so were*
137 *routinely formed from a single GP practice.*

138

139 **Control arm**

140 Participants allocated to the control arm continued GP-led management, and were
141 permitted to continue any current pharmacological or non-pharmacological treatment
142 strategies. New referrals to all other services (e.g. physiotherapy) were also permitted.

143

144 **Outcome measures**

145 The primary outcome measure was the Dysfunction Index of the Short Musculoskeletal
146 Functional Assessment (DI-SMFA)^[16]. This validated, self-administered questionnaire was
147 developed for use in any patients with musculoskeletal dysfunction, recording resultant
148 actual physical limitation. The 34-item questionnaire asks patients to rate their functional
149 performance from 1 – 5 with lower scores indicating improved function. This measure was

150 chosen as it was not joint-specific, and therefore appropriate to use simultaneously in lower
151 limb and lumbar spine musculoskeletal presentations. The primary analysis related to the
152 whole patient sample irrespective of site of pain. Efficacy is the overall effect size obtained
153 from analysis using a mixed model with combined data, not partitioned as per site of pain.
154 Sub-group analyses of site-specific outcomes were undertaken as secondary analyses.
155 Secondary outcomes consisted of: Self-efficacy and exercise health beliefs questionnaire ^[20];
156 Hospital Anxiety and Depression scale (HADS) ^[21]; Short Form McGill Pain questionnaire ^[22];
157 Aggregated Functional Performance Time (AFPT) (a combined measure of walking, stair
158 ascent and descent) ^[23].

159

160 All outcomes were collected at baseline and 6 months follow up. All self-completed
161 outcome measures were also collected post-intervention (and the 6-week equivalent for the
162 control arm). Baseline assessments were undertaken close to the time of pre-planned class
163 commencement to prevent significant discrepancy between time period at follow-up
164 between the control and intervention arms.

165

166 **Statistical Analysis**

167 The data analysis plan was based on an a priori protocol ^[15] and based on Intention to Treat
168 with no interim analyses. For the primary analysis, individual patient responses were
169 modelled using a mixed effects linear regression, allowing for the clustering of outcomes
170 within GP practices (control arm) and exercise classes (intervention arm) by incorporating a
171 random effects term. The mixed model was sufficiently robust to handle potential missing
172 data on the response variable. Differences in mean outcomes from the mixed effects linear
173 regression were used to estimate the effect on the primary outcome of the intervention. To
174 increase the precision of estimates, there was an adjustment for the baseline DI-SMFA score

175 as a covariate in the regression. Participants expressed their primary diagnostic site at
176 baseline (hip/knee/low back pain) which was also included as a covariate to account for
177 variations in the outcome that may be associated with diagnosis.

178 The analysis of all other continuous secondary endpoints followed the same structure as the
179 primary analysis. Whilst the trial was powered to detect a main effect of intervention, a
180 secondary analysis examined the evidence for a difference in the effect of intervention
181 between diagnostic groups, by testing whether an interaction term added to the mixed
182 effects regression model used for the primary analysis was different from zero.

183

184 To better understand its potential benefits, an estimate of the efficacy of the intervention in
185 those patients who were able and willing to comply using a complier averaged causal effect
186 (CACE) approach ^[24] was undertaken. Here, compliance was measured by attendance at the
187 12 scheduled exercise classes, and compliers considered as those attending six or more
188 sessions. This *a priori* decision was taken based on 'typical' class durations in practice
189 whereby most interventions consist of one session per week over a six-week period. The
190 CACE approach compared the mean outcome in compliers on the intervention arm with the
191 mean outcome of a comparable, but unobserved, group of patients on the standard care
192 arm who would have complied with the intervention had they been randomised to do so.

193

194 **RESULTS**

195 **Recruitment**

196 In total 56 practices expressed an interest in participating, and 45 consented to take part,
197 n=23 practices were randomly allocated to the intervention arm, n=22 practices allocated to
198 the control arm. Database searches identified 4986 potential participants who were sent
199 information packs. No data are available for those who were invited but declined to

200 participate as the study team did not have ethical permission to access those data. 664
201 responded and were assessed for eligibility, 232 did not meet the broad inclusion criteria
202 and a further 45 declined to participate after discussing the trial further. 387 people were
203 invited for baseline assessment. A further 25 were screened out at this stage as they did not
204 meet the inclusion criteria or other pathology was suspected and 13 did not attend their
205 initial assessment or respond to alternative appointments. N=349 of the initial 664
206 respondents were recruited onto the trial (52.3%). Figure 1 shows the recruitment flow
207 chart for the study.

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222


223

224

225

226

227 Figure 1: CONSORT diagram showing patient recruitment



228

229

230

231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255

One hundred and seventy participants randomly allocated to the intervention arm and 179 to GP-led care (control arm) were broadly similar at baseline (see table 1). At the 6 months primary end point 27 (16%) participants had withdrawn from the intervention arm and 18 (10%) from the control arm. Total attrition was 13% at the primary end point. No participants reported withdrawal due to exacerbation of symptoms, although one participant attended the first six sessions but did not attend remaining sessions due to pain exacerbation which settled down with rest. She did not however withdraw from the study. One adverse event was reported in the intervention arm when a participant fell whilst alighting an exercise bike; no immediate first aid or further intervention was necessary for this incident.

256

257

258

259 **Table 1: Summary of baseline characteristics (means, SD)**

		<u>Control (n=179)</u>	<u>Intervention (n=170)</u>
261	Gender, number (Male: Female/% male)	75:104/42%	58:112/34%
262	Age (years)	66.5 (8.4)	66.3 (8.1)
263	Height (cm)	167.1 (9.3)	165.8 (9.7)
264	Weight (kg)	81.0 (15.6)	77.6 (14.0)
265	DI-SMFA (Irrespective of site of pain)	60.5 (17.2)	60.4 (16.1)
266	Pain site (DI-SMFA)		
267	Hip/Kn only (n=108)	59.1 (15.7)	56.8 (12.2)
268	LBP only (n=108)	55.8 (15.7)	58.5 (15.4)
269	LBP & hip/kn (n=133)	65.5 (18.4)	64.8 (18.3)
270	AFPT (secs):		
271	50ft walk	13.2 (4.0)	16.5 (7.9)
272	Stair ascent	12.2 (9.5)	13.3 (10.4)
273	Stair descent	5.7 (6.0)	5.6 (6.5)
274	TUAG	9.9 (3.8)	9.9 (3.7)
275	McGill Pain Questionnaire	2.3 (2.1)	2.2 (2.0)
276	HADS		
277	Anxiety	5.7 (3.7)	5.6 (3.7)
278	Depression	4.2 (3.1)	3.9 (2.7)
279	Self-Efficacy	77.7 (9.4)	78.4 (8.9)
280	Pain/discomfort	2.4 (0.8)	2.4 (0.8)
281	Weekly duration on intervention* (mins)	274.4 (17.5)	310.9 (21.3)

279 DI-SMFA – Dysfunction Index Short Musculoskeletal Functional Assessment; AFPT – Aggregate Functional Performance
280 Time; HADS – Hospital Anxiety and Depression Scale. *intervention arm patients reported significantly more activity than
281 those in the control arm

282

283

284

285 Analysis

286 Statistical analysis was performed according to the pre-specified data analysis plan and

287 based on intent-to-treat with no interim or post hoc analyses and no data imputation.

288 Statistical significance is set at the nominal p-value of 0.05. The means and corresponding

289 standard deviations were essentially similar for both the treatment and standard arms,

290 although of note, on average patients in the intervention arm spent more self-reported time

291 per week (approximately 36 minutes) exercising than control participants.

292

293 Primary and secondary outcomes measured at 6 months primary end point

294 Results from analysis using the mixed model adjusted for baseline DI-SMFA scores and pain

295 sites (lower limb, lower back and combined lower back and lower limb) indicate a

296 statistically significant effect of the intervention on DI-SMFA response measured after 6

297 months irrespective of pain site (-3.01; 95%CI: -5.25, -0.76, p=0.01) (Table 2). Specifically,

298 the DI-SMFA score was 3 units lower for a patient on generic exercise and self-management

299 arm compared with a patient on standard GP care arm, adjusting for both baseline DI-SMFA

300 scores and pain site. The significance of this finding will be presented in the discussion.

301

302

303

304

305

306

307

308 **Table 2: Efficacy of exercise on primary and secondary outcomes at primary end point**

309	Analysis	Mean outcome (SD)	Efficacy*	p-value	95% CI	
310		<u>Control</u>	<u>Intervention</u>			
311	A. Primary outcome (DI-SMFA) measured at 6 months					
312	<u>Combined pain sites n=304</u>					
313	Overall efficacy	59.0 (17.9)	56.8 (16.7)	-3.01	0.01	-5.25, -0.76
314	<u>Pain site</u>					
315	Hip/kn only (n=108)	55.7 (14.9)	55.8 (13.0)	-2.28	0.15	-5.64, 0.89
316	LBP only (n=108)	56.3 (20.4)	55.7 (16.7)	-4.17	0.16	-10.00, 1.66
317	LBP & hip/kn (n=133)	62.2 (18.1)	60.2 (14.0)	-3.77	0.02	-6.92, -0.61
318	B. Secondary outcomes measured at 6 months (combined pain sites)					
319	McGill	2.6 (2.1)	2.3 (2.0)	-0.23	0.28	-0.65, 0.19
320	HADS					
321	Anxiety	5.3 (3.8)	5.0 (3.4)	-0.21	0.78	-0.91, 0.68
322	Depression	3.9 (2.9)	3.7 (2.8)	0.05	0.84	-0.42, 0.52
323	Self-Efficacy	79.2 (9.8)	80.5 (9.3)	1.69	0.09	-0.27, 3.65
324	AFPT					
325	50ft walk	13.2 (4.0)	12.5 (2.9)	-0.81	0.10	-1.76, 0.15
326	Stairs ascend	12.7 (9.7)	13.4 (10.77)	0.52	0.97	-2.00, 3.08

327	Stairs descend	5.8 (6.3)	4.9 (4.7)	-1.14	0.12	-2.58, 0.30
328	TUAG	9.6 (3.5)	8.9 (2.7)	-0.82	0.04	-1.61, -0.04

329 *Efficacy: effect size obtained from mixed model analysis

330 DI-SMFA – Dysfunction Index Short Musculoskeletal Functional Assessment; AFPT – Aggregate Functional Performance

331 Time; HADS – Hospital Anxiety and Depression Scale

332

333 Considering each pain site, the efficacy of the intervention on the DI-SMFA scores measured
 334 at 6 months was statistically significant among patients presenting with combined LBP and
 335 hip/knee pain (-3.77; 95% CI: -6.92, -0.61; p=0.02) (Table 2). Despite substantial efficacy
 336 from the intervention among patients with both LBP only, and lower limb hip/knee pain
 337 only, these results were not statistically significant (-4.17; 95%CI: -10.0, 1.66; p=0.16 and –
 338 2.28; 95%CI: -5.64, 0.89; p=0.15 respectively) (Table 2), but this is to be expected as the
 339 study was not powered for these sub-group analyses and are presented for interest only.

340

341 The results indicate no statistically significant effect of the intervention for all the secondary
 342 outcomes measured at 6 months except for AFPT with respect to Timed Up and Go (TUAG).
 343 Here AFPT scores indicated an improvement of about 1 unit for those patients in the
 344 intervention arm relative to those on control, adjusting for baseline AFPT and baseline type
 345 of pain (-0.82; 95%CI: -1.61, -0.04; p=0.04) (Table 2), but this is unlikely to have clinical
 346 significance. Table 3 shows the means (SD) for the secondary outcomes at each pain site
 347 sub-group at 6 months.

348

349

350

351

352

353

354

355

356 **Table 3: Secondary outcomes (means, SD) measured at 6 months for each pain site**

Outcome	Hip/knee only		LBP only		LBP and hip/knee	
	(n=108)		(n=108)		(n=133)	
	<u>Control</u>	<u>Intervtn.</u>	<u>Control</u>	<u>Intervtn.</u>	<u>Control</u>	<u>Intervtn.</u>
McGill	1.9 (1.5)	1.6 (1.6)	2.6 (2.3)	2.2 (2.0)	3.2 (2.3)	2.9 (2.2)
HADS						
Anxiety	4.7 (3.5)	3.9 (3.3)	5.8 (4.0)	5.7 (3.8)	5.5 (3.9)	5.3 (3.1)
Depression	3.5 (2.8)	3.6 (2.6)	3.7 (2.99)	4.1 (2.6)	4.3 (3.1)	3.5 (3.1)
Self-Eff.	78.5 (9.8)	79.9 (9.0)	80.2 (9.3)	80.8 (9.2)	77.7 (9.9)	80.8 (9.8)
AFPT						
50ft walk	12.5 (3.0)	12.7 (3.2)	12.6 (3.6)	11.7 (3.0)	14.2 (4.9)	12.9 (2.5)
Stairs ascend	12.2 (7.3)	13.4 (12.4)	12.2 (9.8)	12.0 (7.0)	13.7 (11.5)	14.7 (11.7)
Stairs descend	5.7 (5.6)	4.7 (4.1)	5.3 (6.0)	5.2 (5.2)	6.2 (6.8)	4.9 (4.8)
TUAG	9.2 (2.6)	8.9 (3.0)	8.6 (3.1)	8.3 (2.3)	10.4 (4.3)	9.4 (2.6)

370

371

372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396

Analysis of secondary outcomes at 6 weeks

Analysis of secondary outcomes measured at 6 weeks, adjusted for baseline outcome and baseline pain sites showed a statistically significant improvement on the McGill pain questionnaire, Self-efficacy for exercise and the anxiety sub-domain of the HAD (Table 4).

The results show evidence of statistically significant effects of the intervention on the McGill Pain Questionnaire measured at 6 weeks (-0.78; 95%CI: -1.30, -0.26; p=0.01): expected McGill score is about 1 unit lower for patients on exercise and self-management compared with patients on standard GP care, but this is unlikely to be clinically significant⁽²²⁾. Similarly, there is evidence of a statistically significant effect of intervention on self-efficacy measured at 6 weeks (3.53; 95%CI: 1.45, 5.62; p=0.01): improvement in expected self-efficacy score of about 3.5 units for patients on exercise and self-management compared with patients on GP care (Table 4).

At 6 weeks, there is a statistically significant effect of intervention on HADS with respect to depression (-0.58; 95%CI: -1.01, -0.14; p=0.01) but not for anxiety (-0.29; 95%CI: -0.92, 0.35; p=0.38) (Table 4). However, HADS scores (both anxiety and depression) were lower at 6 weeks for patients on treatment compared with patients on GP care, this was not retained at six months.

397

398

399

400

401 **Table 4: Secondary outcomes analysis at 6 weeks**

Outcome	Baseline Mean (SD)	6 weeks Mean (SD)	Efficacy	p-value	95% CI
McGill	3.0 (2.5)	2.3 (2.0)	-0.78	<0.01*	-1.30, -
0.26					
HADS					
Anxiety	5.7 (4.1)	5.4 (3.4)	-0.29	0.38	-0.92, 0.35
Depression	4.1 (3.2)	3.5 (2.6)	-0.58	<0.01*	-1.01, -
0.14					
Self-Efficacy	77.6 (10.0)	80.9 (8.6)	3.53	<0.01*	1.45, 5.62

411

412 **Compliance**

413 For the 23 GP surgeries randomised to the experimental intervention, there were 166
414 records (56 males, 110 female) of compliance with treatment allocation, where a complier
415 was defined as one who attended at least six (50%) of the scheduled sessions of exercise.
416 Compliance was considered for most of the patients (83%, 137/166). On average patients
417 attended 8 sessions of exercise and self-management (Table 5).

418

419 **Table 5: Distribution of attendance to intervention for the 12 scheduled sessions**

Att.	0	1	2	3	4	5	6	7	8	9	10	11	12
No.	7	7	4	4	4	3	6	13	16	15	31	31	25

421

422 no. data not available for 4 participants

423

424 **Causal effects of intervention**

425 A complier average causal effect (CACE) analysis provided a measure of the causal effect of
426 exercise and self-management for patients who received the intervention as intended by
427 the original group allocation. Under the potential outcomes framework, CACE analysis
428 compares the mean outcome for compliers in the intervention arm with the mean outcome
429 of similar (but unobserved) group of patients in the control arm who would have complied
430 with intervention had they been randomised to do it (counterfactuals).

431

432 We applied the two-stage instrumental variable regression model adjusting for baseline DI-
433 SMFA scores and pain site (as before) and used baseline diagnosis as instruments. Results
434 for the CACE estimate suggested an improvement in expected DI-SMFA score of about 5.4
435 units for patients on the intervention (exercise and self-management) compared with
436 patients on control (standard GP care).

437

438 The CACE estimate is evidently larger than the ITT estimates, demonstrating a greater
439 benefit of exercise and self-management among participants who complied with the
440 intervention, i.e. attended at least half (6) of the scheduled sessions (12).

441

442 **Primary Outcome / Effectiveness for FASA RCT**

443 In the main effectiveness analyses, the difference in the primary outcome (DI-SMFA score)
444 was positive, indicating a positive treatment effect associated with intervention
445 participants, with a difference in score of 3 units (lower) for the intervention participants.

446

447 **DISCUSSION**

448 This study determined whether FASA, a generic exercise and self-management intervention
449 delivered to participants with hip and knee OA and/or chronic lower back had better clinical
450 outcomes than continued GP-led management. The results demonstrated that participants
451 on the intervention arm had statistically significantly better function at six months
452 compared to those on continued GP care arm as measured by the Dysfunction Index of the
453 Short Musculoskeletal Functional Assessment (DI-SMFA).

454 To our knowledge this is the first rigorous, pragmatic trial, conducted and analysed
455 according to a pre-specified protocol^[15] investigating a combined intervention for hip, knee
456 and/or chronic lower back pain. The trial recruited participants from primary care with a
457 variety of socio-demographic profiles, and with co-morbidities typical of an older population
458 affected by chronic and degenerative musculoskeletal disease. The group intervention was
459 integrated into out-patient physiotherapy departments, was delivered by Chartered
460 Physiotherapists, and consisted of simple exercises and an interactive educational self-
461 management programme based on behaviour change theory.

462

463 The novelty of this trial was the participant cohort presented with hip, knee or lower back
464 pain or a combination of these, and were treated with a generic programme. Trials typically
465 recruit individuals with either one of these presentations, or in some cases with hip and
466 knee OA pain. This approach is unlikely to reflect typical presentation, when many patients
467 with chronic, degenerative joint pain either experience concurrent dysfunction in multiple
468 joints, or over time develop such dysfunction^[25, 26]. Furthermore, management guidelines
469 for each of these presentations recommend similar approaches, namely exercise, education

470 and self-management, so combining patient presentations seems an appropriate use of
471 resources.

472

473 The results demonstrated that participating in the FASA intervention had a statistically
474 significant beneficial effect at the 6-month primary end point on function (DI-SMFA). Whilst
475 the study was not powered to detect significant changes within sub-groups, it is interesting
476 to note that those participants who appeared to benefit most from the intervention had
477 both low back pain and peripheral joint pain and a higher DI-SMFA score. Our previous work
478 with healthcare professionals to determine the acceptability of the generic FASA
479 intervention, highlighted professionals had some concerns that it may not be suitable for
480 people with LBP ^[27]. This may indicate that professionals' perceptions are in some cases
481 over-cautious regarding their management of people with low back pain when generic
482 approaches to activity may be appropriate. This does not detract from evidence regarding
483 benefits of stratified management of low back pain, which supports tailored care according
484 to biopsychosocial presentation ^[28], but does highlight the benefit of simple self-
485 management approaches.

486

487 Whilst the results demonstrated participants in the FASA intervention showed statistically
488 significant improvements in function at 6 months post-intervention, the clinical implications
489 are less clear due to limited definitive evidence on the minimum clinically important
490 difference (MCID) for the DI-SMFA.

491

492 some authors have suggested that the MCID for quality of life measures (e.g. SF-36) are
493 either 3-5 points change in score (based on a 0-100 scale) ^[29], whilst others suggest
494 approximately half of a standard deviation ^[30], but there is no conclusive evidence to this
495 effect for the DI-SMFA. A recent paper reported use of the Dutch version of the SMFA,
496 which according to the authors has the same item content but a 'different factor structure'
497 ^[31], in a cohort of minor to life-changing trauma patients. The authors reported the
498 minimum important change (MIC) in the disaggregated sub-scales, suggesting an MIC of 8-
499 25 points. The changes seen within FASA whilst statistically significant may not readily
500 translate into clinical significance.

501 The FASA intervention showed limited sustained impact on psychosocial variables. This may
502 be explained by the low levels of anxiety and depression present in the cohort before the
503 intervention, thus resulting in a reduced likelihood of meaningful impact on psychosocial
504 function.

505
506 The strengths of this study were its robust methodology, safety, *a priori* analysis plan and
507 pragmatic design, which included participants typically presenting in primary care, and
508 interventions delivered within NHS physiotherapy departments. The study was limited by
509 the availability of a widely used musculoskeletal outcome measure that was suitable for
510 widespread pain presentations. Whilst the SMFA was validated and appropriate for the
511 study population, the lack of widespread use meant that the MCID was not possible to
512 determine. However, a supplementary qualitative study did document patient reported
513 benefit of the intervention (results to be reported separately). This issue is likely resolved
514 now with the development of the Musculoskeletal Health Questionnaire, which is gaining
515 momentum, and likely to be used ubiquitously in the near future ^[32].

516

517 A further limitation may be the duration of the proposed intervention. NHS services are
518 under immense pressure to cope with increasing demands on musculoskeletal services with
519 limited resources, so interventions that require 12 contact sessions may place
520 unmanageable demand on staff and location resources. However of note is that the original
521 ESCAPE intervention for lower limb OA has undergone widespread implementation in the
522 UK^[33], suggesting that such programmes are supported if associated clinical effectiveness is
523 established. CACE analysis did suggest that patients who attended at least six sessions
524 achieved a significant improvement in their function, so consideration could be given to
525 reducing the number of sessions to facilitate implementation within the NHS, but this would
526 necessitate further robust investigation, and require patients to attend all sessions of a
527 reduced programme with minimal leeway for missed appointments. Health economic data
528 collected within this study (to be presented elsewhere), may provide further insight into the
529 utility of a reduced intervention.

530

531 In summary the FASA intervention resulted in statistically significant functional
532 improvements, six months post-intervention in a cohort of patients with degenerative lower
533 limb and/or low back pain. No other statistically significant benefits of the intervention were
534 noted. We are unable to conclusively suggest that this equates to clinically meaningful
535 difference.

536

537

538

539

540

541

542

543

544

545

546

547 **REFERENCES**

548 1. Andrews G. Should depression be managed as a chronic disease? Br Med J
549 2001;322:419–21.

550 2. Woolf AD, Zeidler H, Haglund U, Carr AJ, Chaussade S, Cucinotta D, et al.
551 Musculoskeletal pain in Europe: its impact and a comparison of population and medical
552 perceptions of treatment in eight European countries. Ann Rheum Dis 2004;63:342–7.

553 3. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-
554 adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990 – 2010: a
555 systematic analysis for the Global Burden of Disease Study 2010. The Lancet.
556 2012;380(9859):2197-2223.

557 4. Jordan KP, Kadam UT, Hayward R, Porcheret M, Young C, Croft P. Annual
558 consultation prevalence of regional musculoskeletal problems in primary care: an
559 observational study. BMC Musculoskeletal Disorders. 2010;11:144.

- 560 5. versus Arthritis. The State of Musculoskeletal Health 2019. Arthritis and Other
561 musculoskeletal conditions in numbers.
562 <https://www.versusarthritis.org/media/14594/state-of-musculoskeletal-health-2019.pdf>
- 563 6. O'Malley PG, Jackson JL, Kroenke K, In Kyu Yoon KI, Hornstein E, Dennis GJ, et al. The
564 value of screening for psychiatric disorders in rheumatology referrals. *Arch Intern Med*
565 1998;158:2357–62
- 566 7. Guccione AA, Felson DT, Anderson JJ, Anthony JM, Zhang Y, Wilson PWF, et al. The
567 effects of specific medical conditions on the functional limitations of elders in the
568 Framingham Study. *Am J Public Health* 1994;84:351–7.
- 569 8. Walsh NE, Pearson J, Healey EL. Physiotherapy management of lower limb
570 osteoarthritis. *British Medical Bulletin*, Volume 122, Issue 1, June 2017, Pages 151–161,
571 <https://doi.org/10.1093/bmb/ldx012>
- 572 9. Roddy E, Jordan KP, Oppong R, et al. Reconsultation, self-reported health status and
573 costs following treatment at a musculoskeletal Clinical Assessment and Treatment Service
574 (CATS): a 12-month prospective cohort study. *BMJ Open* 2016; 6:e011735.
575 doi: 10.1136/bmjopen-2016-011735
- 576 10. National Institute for Health and Care Excellence. Osteoarthritis care and management.
577 CG177. February 2014. <https://www.nice.org.uk/guidance/cg177>
- 578 11. Hurley M, Dickson K, Hallett R, Grant R, Hauari H, Walsh N, Stansfield C, Oliver
579 S. Exercise interventions and patient beliefs for people with hip, knee or hip and knee
580 osteoarthritis: a mixed methods review. *Cochrane Database of Systematic Reviews* 2018,
581 Issue 4. Art. No.: CD010842. DOI: 10.1002/14651858.CD010842.pub2.

- 582 12. Hurley MV, Walsh NE, Mitchell HL, Pittman TJ, Patel A, Williamson E, et al. Clinical
583 effectiveness of a rehabilitation program integrating exercise, self-management, and active
584 coping strategies for chronic knee pain: a cluster randomized trial. *Arthritis Care Res*
585 2007;57:1211–9.
- 586 13. Hurley MV, Walsh NE, Mitchell H, Nicholas J, Patel A. Improvements in physical
587 function were sustained for 2½ years following ESCAPE knee pain: an integrated
588 rehabilitation programme for chronic knee pain. *Arthritis Care Res* 2012;64(2):238–47.
- 589 14. Bandura, A. (1977). Self-efficacy: Toward a unifying theory of behavioral
590 change. *Psychological Review*, 84(2), 191–215. <https://doi.org/10.1037/0033-295X.84.2.191>
- 591 15. Walsh N, Cramp F, Palmer S, Pollock S, Hampson L, Gooberman-Hill R, Green C, Jones
592 L et al. Exercise and self-management for people with chronic knee, hip or lower back pain:
593 a cluster randomised controlled trial of clinical and cost-effectiveness. Study protocol.
594 *Physiotherapy* 2013; 99 352–357
- 595 16. Swiontkowski MF, Engelberg R, Martin DP, Agel J. Short musculoskeletal function
596 assessment questionnaire: validity, reliability and responsiveness. *J Bone Joint Surg Am*
597 1999;81:1245–60
- 598 17. Ponzer S, Skoog A, Bergstrom G. The short musculoskeletal function assessment
599 questionnaire (SMFA). Cross-cultural adaptation, validity, reliability and responsiveness of
600 the Swedish SMFA (SMFA-Swe). *Acta Orthop Scand* 2003;74:756–63.
- 601 18. Eldridge SM, Ashby D, Kerry S. Sample size for cluster randomized trials: effect of
602 coefficient of variation of cluster size and analysis method. *Int J Epidemiol* 2006;35:1292–
603 300.

- 604 19. Finney DA, Carrie Murphy L, Hayes D, Hall AM, Toomey E, McDonough SM,
605 Lonsdale C, Walsh NE, Guerin S, Matthews J. Using intervention mapping to develop a
606 theory-driven, group-based complex intervention to support self-management of
607 osteoarthritis and low back pain (SOLAS). *Implementation Science* 2016 11:56 DOI
608 10.1186/s13012-016-0418-2
- 609 20. Gecht MR, Connell KJ, Sinacore JM, Prohaska TR. A survey of exercise beliefs and
610 exercise habits among people with arthritis. *Arthritis Care Res* 1996;9:82–8.
- 611 21. Zigmond AS, Snaith RP. Hospital anxiety and depression scale. *Acta Psychiatr Scand*
612 1983;67:361–7.
- 613 22. Melzack R. The short-form McGill pain questionnaire. *Pain* 1987;30(2):191–7.
- 614 23. Hurley M, Scott DL, Rees J, Newham DJ. Sensorimotor changes and functional
615 performance in patients with knee osteoarthritis. *Ann Rheum Dis* 1997;56(11):641–8.
- 616 24. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental
617 variables. *J Am Stat Assoc* 1996;91:444–55.
- 618 25. Calders, Patrick, and Ans Van Ginckel. “Presence of Comorbidities and Prognosis of
619 Clinical Symptoms in Knee And/or Hip Osteoarthritis : a Systematic Review and Meta-
620 analysis.” *Seminars in Arthritis and Rheumatism* 47(6) (2018) 805-813
- 621 26. Suri P, Morgenroth DC, Kwok CK, Bean JF, Kalichman L, Hunter DJ. Low back pain and
622 other musculoskeletal pain comorbidities in individuals with symptomatic osteoarthritis of
623 the knee: data from the osteoarthritis initiative. *Arthritis Care Res (Hoboken)*. 2010
624 Dec;62(12):1715-23. doi: 10.1002/acr.20324.

- 625 27. Patel G, Walsh N, Guberman-Hill R. Managing Osteoarthritis in Primary Care.
626 Exploring Healthcare Professionals' Views on a Multiple-Joint Intervention Designed to
627 Facilitate Self-Management. *Musculoskeletal Care* 2014 12 (4):199-209. DOI:
628 10.1002/msc.1074
- 629 28. Hill JC, Whitehurst DG, Lewis M, et al. Comparison of stratified primary care
630 management for low back pain with current best practice (STarT Back): a randomised
631 controlled trial. *Lancet*. 2011;378(9802):1560–1571. doi:10.1016/S0140-6736(11)60937-9
- 632 29. Stewart AL, Greenfield S, Hays RD et al. Functional status and well-being of
633 patients with chronic conditions: results from the medical outcomes study. *JAMA* 1989;262
634 (7) 907- 913
- 635 30. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related
636 quality of life. The remarkable universality of half a standard deviation. *Medical Care*.
637 2003;41:582–592.
- 638 31. de Graaf MW, Reininga IHF, Heineman E, El Moumni M. Minimal important change in
639 physical function in trauma patients: a study using the short musculoskeletal function
640 assessment. *Quality of Life Research* (2020) 29:2231–2239, [https://doi.org/10.1007/s11136-](https://doi.org/10.1007/s11136-020-02476-8)
641 020-02476-8
- 642 32. Hill JC, Kang S, Benedetto E, et al. Development and initial cohort validation of the
643 Arthritis Research UK Musculoskeletal Health Questionnaire (MSK-HQ) for use across
644 musculoskeletal care pathways. *BMJ Open* 2016;6:e012331. doi: 10.1136/bmjopen-2016-
645 012331
- 646 33. ESCAPE-pain. <https://escape-pain.org/>. Accessed July 2020.

Journal Pre-proof

Highlights

- FASA results in a statistically significant improvement in function
- Clinical significance is less clear and requires further investigation
- This generic exercise and education programme may be a viable clinical option

Journal Pre-proof